Effects of ranolazine on left ventricular diastolic and systolic function in patients with chronic coronary disease and stable angina

Hellenic Journal of Cardiology

Volumn 56, Issue 3, 2015, Pages 237-241

  Babalis, Dimitrios ^a   Tritakis, Vlassis ^a   Floros, Georgios ^a   Mouzarou, Aggeliki ^a   Kafkas, Nikolaos ^a   Bampal, Konstantina ^a   Mertzanos, Georgios ^a  

^a KAT HOSPITAL   (Greece)

Author keywords

Coronary disease; Ranolazine; Ventricular function

Indexed keywords

RANOLAZINE; SODIUM CHANNEL BLOCKING AGENT;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; TISSUE DOPPLER IMAGING; TREATMENT DURATION; ANGINA, STABLE; CORONARY DISEASE; DRUG EFFECTS; ECHOGRAPHY; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PULSED DOPPLER ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

AGED; ANGINA, STABLE; CORONARY DISEASE; ECHOCARDIOGRAPHY, DOPPLER, PULSED; FEMALE; HUMANS; MALE; MIDDLE AGED; RANOLAZINE; SODIUM CHANNEL BLOCKERS; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84930065939     PISSN: 11099666     EISSN: 22415955     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119: 480-486.
2. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006; 27: 1341-1381.
3. Michalsen A, Knoblauch NT, Lehmann N, et al. Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina—the role of GNB3 C825T polymorphism. Am Heart J. 2006; 151: 870-877.
4. van Domburg RT, Daemen J, Pedersen SS, et al. Short- and long- term health related quality-of-life and anginal status after randomisation to coronary stenting versus bypass surgery for the treatment of multivessel disease: results of the Arterial Revascularisation Therapy Study (ARTS). EuroIntervention. 2008; 3: 506-511.
5. Kloner RA, Hines ME, Geunes-Boyer S. Efficacy and safety of ranolazine in patients with chronic stable angina. Postgrad Med. 2013; 125: 43-52.
6. Lovelock JD, Monasky MM, Jeong EM, et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res. 2012; 110: 841-850.
7. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery dis ease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34: 2949-3003.
8. Sbarouni E, Voudris V, Georgiadou P, et al. Clinical presentation and management of stable coronary artery disease: insights from the international prospective CLARIFY registry - results from the Greek national cohort. Hellenic J Cardiol. 2014; 55: 442-447.
9. Andrikopoulos G, Parissis J, Filippatos G, et al. Medical management of stable angina. Hellenic J Cardiol. 2014; 55: 272-280.
10. Penman AD, Eadie J, Herron WJ, Reilly MA, Rush WR, Liu Y. The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry. Rapid Commun Mass Spectrom. 1995; 9: 1418-1430.
11. Bers DM, Barry WH, Despa S. Intracellular Na+ regulation in cardiac myocytes. Cardiovasc Res. 2003; 57: 897-912.
12. Chaitman BR, Skettino SL, Parker JO, et al; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004; 43: 1375-1382.
13. Chaitman BR, Pepine CJ, Parker JO, et al; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004; 291: 309-316.
14. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006; 48: 566-575.
15. Figueredo VM, Pressman GS, Romero-Corral A, Murdock E, Holderbach P, Morris DL. Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina. J Cardiovasc Pharmacol Ther. 2011; 16: 168-172.